Latest News

(UroToday.com) There have been significant advances in the delivery of prostate radiotherapy in the past decade, particularly with the use of image guidance. However, in spite of this acute and late genitourinary (GU) and gastrointestinal (GI) toxicities remain a significant issue. For patients undergoing combined high-dose rate (HDR) brachytherapy and external beam radiotherapy (EBRT), there is […]

(UroToday.com) Radical prostatectomy (RP) is a standard treatment for patients with localized prostate cancer. A proportion of patients will experience biochemical recurrence following surgery. In these cases, salvage radiotherapy (ideally, early salvage radiotherapy) is indicated. During the plenary abstract presentation in the Prostate Cancer – Advanced Disease Poster Session at the 2021 American Society of Clinical […]

(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a prostate cancer session ‘Best of Journals’ with Dr. Keyan Salari providing the surgical perspective. Dr. Salari selected two studies assessing active surveillance in Black men with low-risk prostate cancer, and one study assessing the timing of radiation therapy after radical prostatectomy.

(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a prostate cancer session ‘Best of Journals’ with Dr. William Hall providing the radiation oncology perspective.

(UroToday.com) Docetaxel chemotherapy is a standard of care treatment option in metastatic castration-resistant prostate cancer (mCRPC). Docetaxel intravenous infusion is associated with infusion reactions that require the administration of prophylactic steroids, which can cause undesired side effects especially in patients with baseline glucose intolerance or metabolic syndrome. ModraDoc006 is an oral tablet formulation of docetaxel that […]

(UroToday.com) In this poster, the authors presented efficacy and safety results from a phase 2 single-center randomized study of enzalutamide monotherapy versus combination enzalutamide and radium-223 in progressive metatstatic castration-resistant prostate cancer (mCRPC). This combination has been previously published as being safe and resulting in PSA declines that correlated with reductions in bone metabolic markers […]

(UroToday.com) In this panel discussion, the presenters answered questions from the audience on the prior session, which are summarized here. Question: In ovarian cancer, perhaps one of the most effective means to predict response to PARPi is prior response to platinum, irrespective of HRD status. Thoughts for prostate cancer? Dr. Nelson answered that this question […]

(UroToday.com) Stage 1 testicular seminoma, which is defined as pure seminoma confined to the testis with no elevated tumor markers, has an excellent prognosis. Current management has shifted towards surveillance rather than adjuvant radiotherapy or chemotherapy for most patients. Most patients who experience recurrence remain curable with salvage therapies, which typically consist of either radiotherapy or […]

(UroToday.com) The management of stage 2A seminoma has been consistent over the past several years, consisting of either radiotherapy of 30 Gy to the para-aortic and ipsilateral iliac lymph nodes or primary chemotherapy with either three cycles of BEP or four cycles of EP. Cure rates with these approaches are excellent but are also associated with […]

(UroToday.com) Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Unfortunately, up to 50% of these patients are medically ineligible for cisplatin due to low-performance status, renal dysfunction, or other medical comorbidities.  Immune checkpoint blockade is a first-line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose tumors […]